Collaboration and License Agreements	6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreements	3. Collaboration and License Agreements XOMA Transaction In December 2019, the Company entered into a license agreement with Day One Biopharmaceuticals, Inc. (“Day One,” formerly known as DOT Therapeutics-1, Inc.) to grant Day One a worldwide exclusive license of DAY101. The Day One license agreement includes up to $57.0 million in potential pre-commercialization, event-based milestone payments and royalty payments on future sales of DAY101, when and if approved and commercialized, $3.0 million of which was received by the Company prior to the XOMA Transaction (as defined below). Also in December 2019, the Company entered into an agreement to license vosaroxin to Denovo Biopharma LLC (“Denovo”), which includes up to $57.0 million in potential regulatory and commercial milestones, and double-digit royalties on future sales of vosaroxin, when and if approved and commercialized. The potential milestone and royalty payments related to DAY101 and vosaroxin were sold in the XOMA Transaction. On March 22, 2021, the Company entered into a Royalty Purchase Agreement with XOMA (US) LLC (“XOMA”), in which XOMA purchased the potential future milestones and royalties associated with the Day One license agreement and the Denovo license agreement, each as described above (the “XOMA Transaction”). The Company received and recorded as a gain in the statement of operations and comprehensive loss for the year ended December 31, 2021, an upfront payment of $13.5 million, and retained a pre-commercialization, event-based milestone. On March 4, 2024, the Company entered into an Amendment No. 1 (the “Day One Amendment”) to the license agreement with Day One to monetize a pre-commercialization, event-based milestone for $5.0 million, thereby reducing the milestone percentage under the agreement. Also on March 4, 2024, in connection with the entry into the Day One Amendment, the Company entered into an Amendment No. 1 to the Royalty Purchase Agreement with XOMA modifying the economic value-share under the Royalty Purchase Agreement, by which the Company has retained the right, under certain circumstances, to participate in a future pre-commercialization, event-based milestone up to $5.0 million. Pursuant to the Day One Amendment, the Company received and recorded $5.0 million as other income in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2024.

Collaboration and License Agreements

6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

3. Collaboration and License Agreements

XOMA Transaction

In December 2019, the Company entered into a license agreement with Day One Biopharmaceuticals, Inc. (“Day One,” formerly known as DOT Therapeutics-1, Inc.) to grant Day One a worldwide exclusive license of DAY101. The Day One license agreement includes up to $57.0 million in potential pre-commercialization, event-based milestone payments and royalty payments on future sales of DAY101, when and if approved and commercialized, $3.0 million of which was received by the Company prior to the XOMA Transaction (as defined below). Also in December 2019, the Company entered into an agreement to license vosaroxin to Denovo Biopharma LLC (“Denovo”), which includes up to $57.0 million in potential regulatory and commercial milestones, and double-digit royalties on future sales of vosaroxin, when and if approved and commercialized. The potential milestone and royalty payments related to DAY101 and vosaroxin were sold in the XOMA Transaction.

On March 22, 2021, the Company entered into a Royalty Purchase Agreement with XOMA (US) LLC (“XOMA”), in which XOMA purchased the potential future milestones and royalties associated with the Day One license agreement and the Denovo license agreement, each as described above (the “XOMA Transaction”). The Company received and recorded as a gain in the statement of operations and comprehensive loss for the year ended December 31, 2021, an upfront payment of $13.5 million, and retained a pre-commercialization, event-based milestone.

On March 4, 2024, the Company entered into an Amendment No. 1 (the “Day One Amendment”) to the license agreement with Day One to monetize a pre-commercialization, event-based milestone for $5.0 million, thereby reducing the milestone percentage under the agreement. Also on March 4, 2024, in connection with the entry into the Day One Amendment, the Company entered into an Amendment No. 1 to the Royalty Purchase Agreement with XOMA modifying the economic value-share under the Royalty Purchase Agreement, by which the Company has retained the right, under certain circumstances, to participate in a future pre-commercialization, event-based milestone up to $5.0 million.

Pursuant to the Day One Amendment, the Company received and recorded $5.0 million as other income in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2024.